Evidence map›Paper›PMID 30406063›Full record

ArticleFrontiers in pediatrics2018

Neuroprotective Effect of IRL-1620, an Endothelin B Receptor Agonist, on a Pediatric Rat Model of Middle Cerebral Artery Occlusion.

Enrique G Cifuentes, Mary G Hornick, Suresh Havalad, Ramona L Donovan, Anil Gulati

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04046484 phase2completednot on this map

A Prospective, Multicentric, Randomized, Double Blind, Parallel, Saline Controlled Phase II Clinical Study to Compare the Safety and Efficacy of PMZ-1620 Therapy Along With Standard Supportive Care in Subjects of Acute Ischemic Stroke

TypeinterventionalSponsorPharmazz, Inc.Ran2018 to 2019Enrolled40ConditionsAcute Stroke, Cerebral IschemiaArmsNormal Saline along with standard treatment, PMZ-1620 along with standard treatment
NCT04047563 phase3completednot on this mapstarted 2019, after this paper: background citation

A Prospective, Multicentric, Randomized, Double-blind, Parallel, Phase III Clinical Study to Assess Efficacy of PMZ-1620 Along With Standard Treatment in Patients of Acute Ischemic Stroke

TypeinterventionalSponsorPharmazz, Inc.Ran2019 to 2022Enrolled158ConditionsCerebral Ischemia, Cerebral Infarction, Stroke, AcuteArmsNormal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Enrique G CifuentesAdvocate Children's Hospital, Park Ridge, IL, United States.
Mary G HornickDepartment of Pharmaceutical Sciences, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, United States.
Suresh HavaladAdvocate Children's Hospital, Park Ridge, IL, United States.
Ramona L DonovanAdvocate Children's Hospital, Park Ridge, IL, United States.
Anil GulatiDepartment of Pharmaceutical Sciences, Chicago College of Pharmacy, Midwestern University, Downers Grove, IL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cerebral blood flowcerebral infarctionendothelin B receptor agonistsischemic penumbrareperfusionstroke

Identifiers

PMID30406063
PMCPMC6206019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.